Print this page



A Phase II Study of Pazopanib in the Treatment of Osteosarcoma Metastatic to the Lung: The purpose of this study is to determine the 4-month Progression-Free Survival (PFS), with demonstrated increase in tumor doubling time, of eligible subjects treated with pazopanib according to RECIST version 1.1 guidelines. This study is not yet open for participant recruitment.


A Phase II Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma: The purpose of this study is to determine the effectiveness and safety of single agent pazopanib in subjects with chondrosarcoma. This study is currently recruiting participants.


A Phase II Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma: The purpose of this study is to evaluate the effectiveness and safety of single agent pazopanib in subjects with unresectable or metastatic liposarcoma.


The PICASSO 3 Trial is a clinical investigation of Palifosfamide for the treatment of soft-tissue sarcoma. If you have been diagnosed with advanced soft-tissue sarcoma and are 18 years or older, you may be eligible to participate in this trial.


Phase II Study of Metastatic Cancer: NY-ESO-1 is a protein that is expressed in approximately one-third of melanoma, breast, prostate, lung, ovarian, thyroid, and bladder cancers, as well as sarcomas. NY-ESO-1 is mostly found in cancer cells, making it a good target for novel cancer therapies. Therefore, we developed an approach to treating patients with NY-ESO-1-expressing tumors by activating the patients’ immune system and targeting the NY-ESO-1 protein.



Finding Risks, Not Answers, in Gene Tests  | By Denise Grady and Andrew Pollack | September 22,2014

Jennifer was 39 and perfectly healthy, but her grandmother had died young from breast cancer, so she decided to be tested for mutations in two genes known to increase risk for the disease. When a genetic counselor offered additional tests for 20 other genes linked to various cancers, Jennifer said yes. The more information, the better, she thought.

The Huffington Post | By Cavan Sieczkowski | July 17, 2014
Duke, a black Labrador living in Houston, was diagnosed with osteosarcoma in his leg a few years ago. Did you know that sarcoma is the most common cancer among dogs?  Even they deserve better.

ZACH SOBIECH: His memory and mission to help find a cure for childhood cancer endures

Zach Sobiech was a remarkable young man who lost his battle with osteosarcoma just days after his 18th birthday in May of 2013. We should all be reminded to truly live and love each day to the fullest, following Zach's example.


Zach's legacy and amazing spirit lives on through his story, the touching documentary "My Last Days: Meet Zach Sobiech", and the inspirational song he wrote and performed, "Clouds".


BENIGN FIBROIDS or LEIOMYOSARCOMA: Be Sure Before Saying "Yes" to Some Minimally Invasive Surgery Techniques


A word of warning to any woman or her doctor considering uterine morcellation for "fibroids". The attached editorial “Patient safety must be a priority in all aspects of care,” appears in February 2014 issue of The Lancet Oncology (V. 15, N. 2, p. 123). It discusses issues that can arise when employing uterine morcellation and the subsequent potential for the spreading of leiomyosarcoma. ESUN also published an article by Sarah Salem-Robinson, PA-C on this very topic in the January 2014 issue of ESUN. Her article and Dr. Judson’s and Dr. Sugarbaker’s comments regarding it are reproduced here. - Patient safety must be a priority in all aspects of care | Vol 15 February 2014 – Are Routine, Minimally Invasive Surgeries for Fibroids Safe? | By Sarah Salem-Robinson, PA-C | January 2014



It doesn't get much better than a collaboration between Nini Jewels and Alexandra Knight Atelier. Both known for their attention to fine detail and generous spirit, the two teamed in an effort to raise both sarcoma awareness and funds for sarcoma research…with exceptional style no doubt. Supporters had an opporutnity to buy a raffle ticket for a chance to win the Nini Jewels violet sapphire and diamond orchid flower brooch. The piece is a favorite of designer Nini Hale who selected the orchid design for its symbolism of refinement, beauty, peace and strength. The brooch has 290 violet sapphires, 108 Sapphires and 15 Diamonds all set in 18k rose gold and is valued at $26,500. Emily Covey was stunned to hear her name announced as the winner of the spectacular brooch by Great Day Houston's Deborah Duncan the evening of the Catwalk for a Cure gala.

A limited edition adjustable Alexandra Knight python cuff in teal was available to raffle ticket purchases. The beautiful python cuffs were commissioned exclusively for the Amschwand Sarcoma Cancer Foundation and generously donated by Alexandra Knight Atelier to promote sarcoma awareness.





The Amschwand Sarcoma Cancer Foundation is pleased to announce the recipients of the 2013 Commitment to the Cause, Commitment to Care and Sarcoma Survivor of the Year awards.

We are proud to reveal the Johnny O'Leary Family* as recipient of the 2013 Commitment to the Cause award as a grateful acknowledgement of the many contributions they have made to advance sarcoma research in memory of their beloved son Johnny. The Commitment to the Cause award is bestowed annually upon one extraordinary person, family or entity that has made great contributions to the sarcoma and/or cancer community.

We are also happy to share that Dr. Rex Marco has been selected as the first-ever recipient of the Commitment to Care award. Having started his career as a spine surgeon and musculoskeletal oncologist at MD Anderson Cancer Center in Houston in 2000, Dr. Rex Marco is one of the only surgeons in the world with training and expertise in the treatment of patients with complex spinal disorders as well as musculoskeletal tumors. Marco is a Professor in the Department of Orthopaedic Surgery at The University of Texas Medical School at Houston, where he is also the Chief of Spine Surgery and Musculoskeletal Oncology. He has faculty appointments with Baylor College of Medicine, Rice University and the Weill Cornell Medical College/Methodist Hospital Orthopaedic Surgery Residency. Dr. Marco also serves as the Co-Director of the Spine Service at Shriner’s Hospital for Children in Houston. The Commitment to Care award will be presented annually to an outstanding clinician who has exhibited excellence in providing both care and compassion to patients and families affected by sarcoma cancers.

We are thrilled to celebrate thirty years of sarcoma survivorship with University of Houston alum, professional golfer, father and ASCF’S 2013 Sarcoma Survivor of the Year Stuart Hendley. In 1983, Hendley had been on top of the world having been named #1 junior golfer in the United States by Golf Digest magazine. Days later he would be diagnosed with osteosarcoma facing the possibility of never returning to the sport he loved, amputation of his leg and losing his life. In the end, Stuart Hendley would defy each of those odds and more serving as inspiration to other sarcoma patients and cancer survivors.

All awards were presented at the Amschwand Sarcoma Cancer Foundation's annual Catwalk for a Cure gala on November 7th at Hotel ZaZa.

(*Highland Park family keeps son's memory alive by Heather Noel of NeighborsGo, produced by the Dallas Morning News)


In February 2013, the Amschwand Sarcoma Cancer Foundation established the Johnny O’Leary Memorial Fund at the request of Stinelli and Tim O’Leary. Throughout their son Johnny’s 500 day journey battling sarcoma, he positively impacted the lives of thousands. Through the Johnny O’Leary Memorial Fund, Stinelli and Tim hope to continue Johnny’s legacy of making a positive difference in the lives of others. To contribute, please send your checks made out to the Amschwand Sarcoma Cancer to:

2726 Bissonnet Street Ste 240-314

Houston TX 77005


Memo line should read Johnny O’Leary. Credit card donations may be made by phone by calling 713.256.4250.


Rachel is one smart cookie. Faced with the annual challenge of selling Girl Scout Cookies for her local troop, this entrepreneurial scout got creative, and in the process, is not only honing her business skill set, but she is helping patients with cancer. When Rachel learned that Houston-based Amschwand Sarcoma Cancer Foundation (ASCF) provides more than 1000 nights of free short-term housing annually to families visiting her hometown in search of treatment for sarcoma (a rare cancer affecting both children and adults), she pledged to find a way to contribute.

Rachel reached out to ASCF (with mom Rebekah's support) offering to donate purchased cookies to the families affected by sarcoma cancers. "Often people want to support the scouts but for a variety of reasons, they are unable to indulge themselves", says Rebekah. "So that's when we thought those who want to offer support can donate their cookies to Amschwand."

Wasting no time, the eager scout went to work and now almost 50 boxes later, Rachel has ensured that each family participating in the ASCF's housing program will be welcomed to Houston with (among other things) a delicious box of Girl Scout Cookies.

No doubt, big things are in store for Rachel. With a little ingenuity and a giving heart, her philanthropic future is bright...and ASCF and the families we serve are grateful to be on the receiving end of her generous spirit.




Words of wisdom from the Amschwand Sarcoma Cancer Foundation’s 2012 Celebration of Survivorship Honoree Alexandra Knight generously shared by CultureMap’s Shelby Hodge. Don’t wait for the diagnosis, accept Alex’s challenge today. It will change your life.


Lessons learned: Cancer gave Alexandra Knight another chance to live life to fullest




A mom's terrible choice: her life or her child's

New York Post | Kate Briquelet | March 30, 2014

A beautiful (and bittersweet) story about a young woman who was told she'd never get pregnant after going through chemotherapy treatment for sarcoma. She miraculously became pregnant but ultimately had to choose her life or her baby's when the sarcoma returned.  Her story will be featured in a documentary by Christopher Henze called 40 Weeks.


Getting Cancer Wrong: Solving Cancer, You Can't Cure What You Don't Understand

Newsweek | By Alexander Nazaryan | March 20, 2014

"The enemy remains poorly defined" in the war against cancer.  Since President Nixon signed the National Cancer Act in 1971 it is true that there have been advancements still we continue to develop cancer at an alarming rate and treatment breakthroughs (especially for "rare cancers" like sarcoma) can be elusive.  This Newsweek article discusses how one defeats a disease that is constantly evolving and developing resistance to our weapons.



Regorafenib Approved for Gastrointestinal Stromal Tumors

Medscape | Zosia Chustecka | February 25, 2013

The indication for the oral targeted agent regorafenib (Stivarga, Bayer) has been expanded by the US Food and Drug Administration (FDA); it is now approved for the treatment of gastrointestinal stromal tumors (GIST).


Zach's Story: Finding peace through music

Zach Sobiech, of Lakeland, Minn., doesn’t go far without his guitar in tow. Zach was diagnosed with osteosarcoma in 2009 at age 14.  Facing months to live, Zach is turning to music - writing and performing songs as a way to say goodbye to his friends and family.


European Medicines Agency Accepts Marketing Application for Masitinib in the Treatment of Gleevec(R) resistant Gastro-Intestinal Stromal Tumor

Business Wire | October 4, 2012 | Paris

AB Science SA (NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors (PKIs), announced that the European Medicines Agency (EMA) has accepted for review a Marketing Authorization Application (MAA) for masitinib in the treatment of patients with Gleevec(R)-resistant gastro-intestinal stromal tumors (GIST).


The Silver Lining Video Series: How to Talk With Children About Cancer

By Hollye Jacobs | September 27, 2012

As a Pediatric and Adult Palliative Care Nurse and Social Worker with graduate degrees in Bioethics and Child Development nurse, Hollye Harrington Jacobs is highly qualified to write about the medical aspects of a cancer diagnosis. But the creator/writer of The Silver Pen blog is especially qualified to share the emotional, physical and practical aspects of a cancer diagnosis after being diagnosed with breast cancer in 2010. Hollye provides insight and inspiration about her battle with breast cancer through humor, humility and emotion. In the first of her Silver Lining Video Series, Hollye shares her expertise and personal experience about explaining cancer to children. “My greatest hope for this video is that it will provide some tools to help anyone who is diagnosed with cancer talk with the children in their lives.”


Kevin Rhodes lives fearlessly despite his cancer challenges

Miami-Dade Community Newspapers |By Raquel Garcia | September 18, 2012

Sarcoma survivor Kevin Rhodes has met many challenges in his life and continues to be an inspiration to many. The Amschwand Sarcoma Cancer Foundation has been proud to play a role in Kevin’s treatment and recovery process, providing housing in the Texas Medical Center for Kevin and his family through ASCF’s “Shared Families” corporate apartment program.


Christian Bale becomes real-life superhero for boy with cancer

By Lizbeth Scordo | Monday, September 10, 2012

Four-year old Jayden Barber was diagnosed with Ewings Sarcoma bone cancer in early 2010. “The Dark Knight Rises” actor Christian Bale heard Jayden’s story and presented the diehard Batman fan with a trip to Disneyland. Jayden got an extra surprise when Bale himself joined Jayden and his family for lunch.



Motherhood Exaggerated, by Judith Hannan

When Judith Hannan’s daughter was diagnosed with Ewing’s Sarcoma at the age of eight, their lives were turned upside down. The very candid autobiographical book Motherhood Exaggerated chronicles the journey her daughter and their family take when faced with the shock and uncertainty that comes with a cancer diagnosis.


Sarcoma Awareness Month

Suzie Siegel | June 30, 2012

U.S. Kathy Castor, D-FL, has introduced a resolution, H.RES. 722, to support the designation of July as Sarcoma Awareness Month.


New Marker, New Target in Ewing's Sarcoma

ScienceDaily | June 29, 2012 — Ewing's sarcoma is a bone cancer commonly diagnosed in about 250 U.S. teenagers per year. If early chemotherapy is effective, improvement can be durable. But for children and teens who respond poorly to a first attempt at chemotherapy or if the disease spreads, long-term survival can be less than 10 percent. A University of Colorado Cancer Center study published this week in the journal Molecular Cancer Research shows an important difference that may explain why some respond and some don't: the existence of high levels of the protein EYA3.


Doctors Win Outstanding Care Awards from the Sarcoma Alliance

PRWeb Press Release via | Published 09:00 a.m., Thursday, June 28, 2012

The Sarcoma Alliance announced today that three doctors -- Gina D'Amato in Atlanta, Jonathan Trent in Miami and Peter Anderson in Houston -- had won its Outstanding Care Awards.


Sarcoma Alliance Discusses Sex and the Cancer Patient

PRWEB | June 26, 2012

Today, the Sarcoma Alliance published an article about sexuality from an expert on quality-of-life issues at M.D. Anderson Cancer Center.


ND starts Uplifting Athletes chapter

By Matt Fortuna | May, 7, 2012

Notre Dame is one of four new schools to start chapters of Uplifting Athletes, a nonprofit in which college football teams fight rare diseases by raising awareness. The Irish have chosen Ewing's sarcoma in honor of fan Sam Grewe. Ewing's sarcoma is a rare malignant bone cancer that affects children.


Pazopanib: First Drug for Sarcoma in Decades

By Zosia Chustecka, Medscape Medical News | May 3, 2012

Pazopanib (Votrient), approved last week in the United States for the treatment of advanced soft tissue sarcomas, is the first new drug option for these patients in decades.  Pazopanib, which targets VEGF, PDGF, and several tyrosine kinases, is already approved for the treatment of kidney cancer.


Brave Boy, 12, Calls Halt to Cancer Treatment

By Amanda Carey | ABC News Blogs | February 23, 2012

A 12-year old boy who has battled a rare form of cancer [sarcoma] since he was 7 has made a bold decision. He is stopping his treatments so he can go home and be with his family.


Cancer Patients Fume Over Counterfeit Avastin

By KATIE MOISSE (@katiemoisse) ( | February 15, 2012

Cancer patients are furious that a counterfeit version of the drug Avastin has landed in U.S. clinics.  Avastin, which is made by the California-based company Genentech, is used in combination with chemotherapy to treat cancers of the colon, brain, kidneys and lungs. But the counterfeit lacks the tumor-starving ingredient some patients need to survive.


MD Anderson expands its game

By TODD ACKERMAN ©2011 HOUSTON CHRONICLE | November 28, 2011

The University of Texas M.D. Anderson Cancer Center is stocking up on scientists and plunging into the business of drug development, a major upgrade to areas that have lagged considerably behind the institution's clinical-care reputation.


Sarcoma Alliance Offers Tips for Supporting Cancer Patients Online

Tampa, FL (PRWEB) | November 28, 2011

The Sarcoma Alliance, a national nonprofit organization, has collected suggestions from professionals on how people can best support one another, even when there's no facilitator to guide the group.


15-Year-Old Inspires Dozens to Donate Blood and Sign Up for Bone Marrow Registry

By Ryan Macasero | November 28, 2011

Zoe Inciong is determined to beat a rare bone cancer


MD Anderson expands its game

By TODD ACKERMAN ©2011 HOUSTON CHRONICLE | Updated 06:00 a.m., Monday, November 28, 2011

The University of Texas M.D. Anderson Cancer Center is stocking up on scientists and plunging into the business of drug development, a major upgrade to areas that have lagged considerably behind the institution's clinical-care reputation.


Today’s Extra Yard: New York Giants rookie tackled cancer

November 18, 2011

New York Giants Mark Herzlich shares his inspirational story of his successful battle with Ewing’s sarcoma on NBC’s Today Show.


Stem Cell–Associated Proteins Can Identify Origins of Pediatric Tumors

Allen Press Publishing Services | Released: November 9, 2011 10:00 AM EST

Newswise — Sarcomas are cancerous tumors of the soft tissue and bone. Although they are rare in children, they present a medical challenge when they occur.


Ridaforolimus Promising for Treating Advanced Sarcomas

November 08, 2011

Ridaforolimus treatment is associated with promising clinical benefit response and progression-free survival for patients with advanced sarcomas, according to a study published online Nov. 7 in the Journal of Clinical Oncology.


Mark Herzlich story on '60 Minutes'

By Mike Mazzeo Special to | Updated: October 28, 2011, 6:27 PM ET

Archive EAST RUTHERFORD, N.J. -- New York Giants linebacker Mark Herzlich's inspirational story of how he defied the odds, overcoming cancer to play in the NFL, will be aired on "60 Minutes" this Sunday evening.


Click here to watch the CBS 60 Minutes segment.


ZIOPHARM Presents Promising Preclinical Pediatric Sarcoma Data with Oral and IV Palifosfamide at the 2011 CTOS/MSTS Meeting 29 Oct 2011

NEW YORK, NY, USA I October 28, 2011

Presentation of promising preclinical data with palifosfamide (Zymafos™ or ZIO-201) in a pediatric sarcoma model.


Sarcoma Alliance Supports Doctors and Scientists Who Work Together to Better Treat Patients

Chicago, Illinois (PRWEB) | October 29, 2011

Specialists attending what may be the largest sarcoma conference ever held discuss ways to improve and increase clinical trials for the rare cancer.


Threshold Pharmaceuticals Reports Further Promising Data With TH-302 in Soft Tissue Sarcoma Update of Fully Enrolled Phase 1/2 Clinical Trial at the Connective Tissue Oncology Society Meeting

South San Francisco, California | Oct 28, 2011

Threshold Pharmaceuticals, Inc. /quotes/zigman/111908/quotes/nls/thld THLD +1.86% yesterday announced clinical trial results related to Threshold's Phase 3 clinical stage hypoxia-activated prodrug, TH-302.


Sarcoma Alliance Urges Patients to Go to Multidisciplinary Centers

Chicago, IL (PRWEB) | October 24, 2011

As an international conference gets underway, the nonprofit organization updates its list of sarcoma centers and gives grants to people who have to travel to one.


Clinical test of new antibody drug for sarcoma to start in France

Mainichi Daily News | October 18, 2011
TOKYO (Kyodo) -- Onco Therapy Science Inc., a research-based venture in Kawasaki, Kanagawa Prefecture, said Monday it will start a clinical test of new antibody drug for treatment of synovial sarcoma, a type of cancer for which there has been no cure, ....


Cancer survivor sings to inspire hope

Shreveport Times | October 18, 2011

His current tour involves stops sponsored by Picasso3, a potential sarcoma drug in clinical trials around the United States. Feist-Weiller is one of the trial sites. Lustman also will perform his entire operetta in Palm Beach, Fla., during this tour.


Novel Approaches and Agents Making Headway against Sarcoma

By Susan London | October 15, 2011, Volume 2, Issue 15, Supplement

Novel approaches and agents reported at the ASCO 2011 Annual Meeting are improving outcomes in sarcoma, a heterogeneous disease with historically poor outcomes, according to William D. Tap, MD, Section Chief of Sarcoma Oncology at Memorial Sloan-Kettering Cancer Center in New York.


Sarcoma Alliance Updates Directory of Nonprofit Organizations

Mill Valley, CA (PRWEB) | September 30, 2011

The Alliance also gives tips on how to find nonprofits that fit the needs of people affected by sarcoma, a rare cancer...


CytRx to Substantially Increase Patient Enrollment in INNO-206 Phase 1b/2 Clinical Trial Principally in Patients with Soft Tissue Sarcomas

press release | Sept. 26, 2011, 8:30 a.m. EDT

Changes Designation of Clinical Trial to Phase 1b/2 Allowing for More Accurate Estimate of Response Rate ....


Nanobiotix Starts Clinical Trial with Lead Product NBTXR3

press release | Sept. 13, 2011, 8:00 a.m. EDT

A Completely New Cancer Treatment to Be Tested in Patients with Soft Tissue Sarcoma ....


Local Swim Clubs 'Go Gold' to Cure Kids Cancer

By Greg Kulaga | August 17, 2011

Little Silver girl with Ewing's Sarcoma inspires awareness campaign to research better treatments for childhood cancer.


Kris Carr: Crazy Sexy Entrepreneur

By MIREILLE SILCOFF | Published: August 12, 2011

Carr took her documentary’s title, “Crazy Sexy Cancer,” from the one she used for the update e-mails she’d been sending to family and friends since her diagnosis. The film premiered at the South by Southwest Festival and then was shown on the cable network TLC in August 2007. It is the presentation of one woman’s universe as a classic hero’s journey. ....[Click on the article title above to read more and/or click here to view the documentary's trailer]


influx of funding impels collaborative explorations to study sarcoma as behavior model for other cancers

By Fran Lowry |September 1, 2010

This rare cancer finally sheds its FDA designation as an orphan disease.


Cycle for Survival Founder Jennifer Goodman Linn Legacy Lives On

Carolyn Everson | July 21, 2011

Jennifer Goodman Linn lost her battle to sarcoma in July 2011, but her inspirational legacy continues on in the organization she founded, Cycle for Survival.


You can also listen to Jennifer's inspirational story in her own words in this 2010 interview that aired on the Today Show with Kathie Lee Gifford and Hoda Kotb.


Merck and ARIAD Announce Presentation of Results of Phase III SUCCEED Trial at American Society of Clinical Oncology Annual Meeting

Whitehouse Station, N.J. and CAMBRIDGE, MA | June 6, 2011- Merck (NYSE:MRK)




Research Grant Applications: Applicants, please read this important note.

RESOURCES (For additional Resources, see our Links/Resources Page)

Download the Sarcoma Survivors Starter Notebook in PDF format here.

MD Anderson Cancer Center’s KNIT program (Kids Need Information Too) provides information to young children with a parent who has been diagnosed with cancer (an unfortunate reality for many children of sarcoma patients). The video shows clips of several families and provides helpful hints on what to do and what not to do when talking to your children about your cancer. This resource is highly recommended.

ASCF Corporate Housing Program lessens both financial and emotional toll for out of town sarcoma patients seeking treatment, follow-up and care from Houston specialists.


Dr. Eugenie S. Kleinerman, Professor and Head of the Division of Pediatrics at The University of Texas M. D. Anderson Cancer Center answers a few questions about pediatric sarcomas. Read more

Dr. Michael J. Reardon, surgeon at Houston's Methodist Debakey Heart Center, answers questions on cardiac angiosarcoma. Read more.




Previous page: ASCF Press Kit
Next page: News Archive